|
1
|
Trépo C, Chan HLY and Lok A: Hepatitis B
virus infection. Lancet. 384:2053–2063. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kwon H and Lok AS: Hepatitis B therapy.
Nat Rev Gastroenterol Hepatol. 8:275–284. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lo AO and Wong GL: Current developments in
nucleoside/nucleotide analogues for hepatitis B. Expert Rev
Gastroenterol Hepatol. 8:607–622. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Buti M, Gane E, Seto WK, Chan HL, Chuang
WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, et al:
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the
treatment of patients with HBeAg-negative chronic hepatitis B virus
infection: A randomised, double- blind, phase 3, non-inferiority
trial. Lancet Gastroenterol Hepatol. 1:196–206. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chan HL, Fung S, Seto WK, Chuang WL, Chen
CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, et al:
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the
treatment of HBeAg-positive chronic hepatitis B virus infection: A
randomised, double-blind, phase 3, non-inferiority trial. Lancet
Gastroenterol Hepatol. 1:185–195. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Agarwal K, Brunetto M, Seto WK, Lim YS,
Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, et al: 96
weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil
fumarate for hepatitis B virus infection. J Hepatol. 68:672–681.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM,
Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, et al: Entecavir treatment
reduces hepatic events and deaths in chronic hepatitis B patients
with liver cirrhosis. Hepatology. 58:1537–1547. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gordon SC, Lamerato LE, Rupp LB, Li J,
Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V,
Boscarino JA, et al: Antiviral therapy for chronic hepatitis B
virus infection and development of hepatocellular carcinoma in a US
population. Clin Gastroenterol Hepatol. 12:885–893. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lok AS, McMahon BJ, Brown RS Jr, Wong JB,
Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA,
et al: Antiviral therapy for chronic hepatitis B viral infection in
adults: A systematic review and meta-analysis. Hepatology.
63:284–306. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mak LY, Seto WK, Lai CL and Yuen MF: DNA
polymerase inhibitors for treating hepatitis B: A safety
evaluation. Expert Opin Drug Saf. 15:383–392. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wong GL, Tse YK, Wong VW, Yip TC, Tsoi KK
and Chan HL: Long-term safety of oral nucleos(t)ide analogs for
patients with chronic hepatitis B: A cohort study of 53,500
subjects. Hepatology. 62:684–693. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cathcart AL, Chan HL, Bhardwaj N, Liu Y,
Marcellin P, Pan CQ, Shalimar Buti M, Cox S, Parhy B, et al: No
resistance to tenofovir alafenamide detected through 96 Weeks of
treatment in patients with chronic hepatitis B infection.
Antimicrob Agents Chemother. 62:e01064–18. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sax PE, Wohl D, Yin MT, Post F, DeJesus E,
Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, et al:
Tenofovir alafenamide versus tenofovir disoproxil fumarate,
coformulated with elvitegravir, cobicistat, and emtricitabine, for
initial treatment of HIV-1 infection: Two randomised, double-blind,
phase 3, non-inferiority trials. Lancet. 385:2606–2615.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mills A, Arribas JR, Andrade-Villanueva J,
DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga
JV, Brunetta J, et al: Switching from tenofovir disoproxil fumarate
to tenofovir alafenamide in antiretroviral regimens for
virologically suppressed adults with HIV-1 infection: A randomised,
active-controlled, multicentre, open-label, Phase 3,
non-inferiority study. Lancet Infect Dis. 16:43–52. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Agarwal K, Fung SK, Nguyen TT, Cheng W,
Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM,
et al: Twenty-eight days safety, antiviral activity, and
pharmacokinetics of tenofovir alafenamide for treatment of chronic
hepatitis B infection. J Hepatol. 62:533–540. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA,
Nguyen HA, Nguyen KK, Levitt BS and Nguyen MH: Renal dysfunction in
chronic hepatitis B patients treated with adefovir dipivoxil.
Hepatology. 50:727–734. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jung YK, Yeon JE, Choi JH, Kim CH, Jung
ES, Kim JH, Park JJ, Kim JS, Bak YT and Byun KS: Fanconi's Syndrome
associated with prolonged adefovir dipivoxil therapy in a hepatitis
B virus patient. Gut Liver. 4:389–393. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Viganò M, Brocchieri A, Spinetti A,
Zaltron S, Mangia G, Facchetti F, Fugazza A, Castelli F, Colombo M
and Lampertico P: Tenofovir-induced Fanconi syndrome in chronic
hepatitis B monoinfected patients that reverted after tenofovir
withdrawal. J Clin Virol. 61:600–603. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mauss S, Berger F, Filmann N, Hueppe D,
Henke J, Hegener P, Athmann C, Schmutz G and Herrmann E: Effect of
HBV polymerase inhibitors on renal function in patients with
chronic hepatitis B. J Hepatol. 55:1235–1240. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
World Medical Association Declaration of
Helsinki. Ethical principles for medical research involving human
subjects. JAMA. 310:2191–2194. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Drafting Committee for Hepatitis
Management Guidelines and the Japan Society of Hepatology. JSH
Guidelines for the management of hepatitis B virus infection.
Hepatol Res. 44 (Suppl S1):S1–S58. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Committee of the Japan Diabetes Society on
the Diagnostic Criteria of Diabetes Mellitus. Seino Y, Nanjo K,
Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N,
Iwamoto Y, et alReport of the committee on the classification and
diagnostic criteria of diabetes mellitus. J Diabetes Investig.
1:212–228. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Levey AS, Stevens LA, Schmid CH, Zhang Y,
Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene
T, et al: A new equation to estimate glomerular filtration rate.
Ann Intern Med. 150:604–612. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Barth JH, Jones RG and Payne RB:
Calculation of renal tubular reabsorption of phosphate: The
algorithm performs better than the nomogram. Ann Clin Biochem.
37:79–81. 2000.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bervoets AR, Spasovski GB, Behets GJ, Dams
G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME and
D'Haese PC: Useful biochemical markers for diagnosing renal
osteodystrophy in predialysis end-stage renal failure patients. Am
J Kidney Dis. 41:997–1007. 2003.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ureña P, Hruby M, Ferreira A, Ang KS and
de Vernejoul MC: Plasma total versus bone alkaline phosphatase as
markers of bone turnover in hemodialysis patients. J Am Soc
Nephrol. 7:506–512. 1996.PubMed/NCBI
|
|
27
|
Hagiwara S, Nishida N, Ida H, Ueshima K,
Minami Y, Takita M, Komeda Y and Kudo M: Switching from entecavir
to tenofovir alafenamide versus maintaining entecavir for chronic
hepatitis B. J Med Virol. 91:1804–1810. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Uchida Y, Nakao M, Tsuji S, Uemura H,
Kouyama JI, Naiki K, Motoya D, Sugawara K, Nakayama N, Imai Y, et
al: Significance of switching of the nucleos(t)ide analog used to
treat Japanese patients with chronic hepatitis B virus infection
from entecavir to tenofovir alafenamide fumarate. J Med Virol.
92:329–338. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC,
Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS and Kao JH: High levels
of hepatitis B surface antigen increase risk of hepatocellular
carcinoma in patients with low HBV load. Gastroenterology.
142:1140–1149.e3; quiz e13-4. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Choi J, Kim HJ, Lee J, Cho S, Ko MJ and
Lim YS: Risk of hepatocellular carcinoma in patients treated with
entecavir vs. tenofovir for chronic hepatitis B: A Korean
nationwide cohort study. JAMA Oncol. 5:30–36. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yip TC, Wong VW, Chan HL, Tse YK, Lui GC
and Wong GL: Tenofovir is associated with lower risk of
hepatocellular carcinoma than entecavir in patients with chronic
HBV infection in China. Gastroenterology. 158:215–225.e6.
2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Murata K, Asano M, Matsumoto A, Sugiyama
M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki
T, et al: Induction of IFN-λ3 as an additional effect of
nucleotide, not nucleoside, analogues: A new potential target for
HBV infection. Gut. 67:362–371. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tanji N, Tanji K, Kambham N, Markowitz GS,
Bell A and D'agati VD: Adefovir nephrotoxicity: Possible role of
mitochondrial DNA depletion. Hum Pathol. 32:734–740.
2001.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Izzedine H, Launay-Vacher V, Isnard-Bagnis
C and Deray G: Drug-induced Fanconi's syndrome. Am J Kidney Dis.
41:292–309. 2003.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sun L, Yi D, Sun W and Wang C:
Retrospective analysis of the clinical characteristics of adefovir
dipivoxil-induced Fanconi's syndrome in the Chinese population. J
Clin Pharm Ther. 45:722–728. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Servais A, Lechat P, Zahr N, Urien S,
Aymard G, Jaudon MC, Deray G and Isnard Bagnis C: Tubular
transporters and clearance of adefovir. Eur J Pharmacol.
540:168–174. 2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sanyal A, Bass N, Mullen K, Poordad F,
Shaw A, Merchant K, Bortey E, Forbes WP and Huang S: A drug
transporter gene polymorphism predicts renal tubular toxicity in
patients with chronic hepatitis B on long-term adefovir and
lamivudine combination. J Hepatol. 52(S7)2010.
|
|
38
|
Fernandez-Fernandez B, Montoya-Ferrer A,
Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V,
Ortiz-Martin N, Parra-Rodriguez A, Selgas R, et al: Tenofovir
nephrotoxicity: 2011 update. AIDS Res Treat.
2011(354908)2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Papaleo A, Warszawski J, Salomon R,
Jullien V, Veber F, Dechaux M and Blanche S: Increased beta-2
microglobulinuria in human immunodeficiency virus-1-infected
children and adolescents treated with tenofovir. Pediatr Infect Dis
J. 26:949–951. 2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Gatanaga H, Tachikawa N, Kikuchi Y, Teruya
K, Genka I, Honda M, Tanuma J, Yazaki H, Ueda A, Kimura S and Oka
S: Urinary beta2-microglobulin as a possible sensitive marker for
renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum
Retroviruses. 22:744–748. 2006.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dauchy FA, Lawson-Ayayi S, de La Faille R,
Bonnet F, Rigothier C, Mehsen N, Miremont-Salamé G, Cazanave C,
Greib C, Dabis F and Dupon M: Increased risk of abnormal proximal
renal tubular function with HIV infection and antiretroviral
therapy. Kidney Int. 80:302–309. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Shimizu M, Furusyo N, Ikezaki H, Ogawa E,
Hayashi T, Ihara T, Harada Y, Toyoda K, Murata M and Hayashi J:
Predictors of kidney tubular dysfunction induced by adefovir
treatment for chronic hepatitis B. World J Gastroenterol.
21:2116–2123. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Fong TL, Lee BT, Tien A, Chang M, Lim C,
Ahn A and Bae HS: Improvement of bone mineral density and markers
of proximal renal tubular function in chronic hepatitis B patients
switched from tenofovir disoproxil fumarate to tenofovir
alafenamide. J Viral Hepat. 26:561–567. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kaneko S, Kurosaki M, Tamaki N, Itakura J,
Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, et al:
Tenofovir alafenamide for hepatitis B virus infection including
switching therapy from tenofovir disoproxil fumarate. J
Gastroenterol Hepatol. 34:2004–2010. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tamaki N, Kurosaki M, Nakanishi H, Itakura
J, Inada K, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa
Y, et al: Comparison of medication adherence and satisfaction
between entecavir and tenofovir alafenamide therapy in chronic
hepatitis B. J Med Virol. 92:1355–1358. 2020.PubMed/NCBI View Article : Google Scholar
|
